Objective-Leukotriene B 4 (LTB 4 ) has been implicated in the trafficking of monocytes to inflammatory pathologic conditions, such as transplant rejection and atherosclerosis. The aim of this study was to determine the mechanisms by which LTB 4 contributes to monocyte capture from the circulation. Methods and Results-In in vitro and in vivo vascular models, the lipid chemoattractant LTB 4 was an equipotent agonist of monocyte adhesion compared with the chemokine monocyte chemoattractant protein-1 (MCP-1). Adenoviral gene transfer of specific endothelial adhesion molecules and blocking monoclonal antibody studies demonstrated that LTB 4 triggers both ␤ 1 -and ␤ 2 -integrin-dependent adhesion. Flow cytometry studies suggested that changes in integrin avidity or affinity, rather than alterations of integrin surface expression, were responsible for the chemoattractant-triggered arrest. Surprisingly, in contrast to the peptide chemokine MCP-1, LTB 4 did not activate the phosphoinositide 3-kinase pathway, which is a functionally critical step in chemokine-triggered effector functions.
L eukotriene B 4 (LTB 4 ), a product of the 5-lipoxygenase pathway of arachidonic acid metabolism, is associated with multiple inflammatory pathologic conditions, including human arthritis, asthma, allograft rejection, and atherosclerosis. [1] [2] [3] [4] Recently, investigators have begun to use receptor antagonists to address a causal link between LTB 4 production and disease progression in animal models. Several of these studies have suggested a specific role for LTB 4 in the contribution of monocytes to inflammatory pathologic conditions. For example, an LTB 4 receptor antagonist markedly prolonged cardiac allograft survival in mice. 3 Immunohistochemical analysis was most notable for decreased monocyte staining for the ␤ 2 -integrin CD11b, a potential marker of monocyte activation, suggesting that LTB 4 contributes to monocyte effector functions during allograft rejection. Similarly, LTB 4 has been more closely tied to atherogenesis, because plaques produce LTB 4 4 and treatment of atherosclerosis-prone mice with an LTB 4 receptor antagonist decreased both monocyte infiltration into lesions and lesion size. 5 In the atherosclerosis studies, a pharmacologic receptor antagonist decreased ␤ 2 -integrin expression (CD11b) of circulating monocytes in a dose-dependent manner. This finding sug-gests that LTB 4 might contribute to plaque development by enhancing monocyte recruitment secondary to LTB 4 -induced upregulation of ␤ 2 -integrin expression. Of note, however, knockout studies of both ␤ 2 integrins and their endothelial counterligand, intercellular adhesion molecule-1 (ICAM-1), suggest a relatively minor role for this adhesion pathway in atherosclerotic lesion development. 6, 7 In contrast, the ␤ 1integrin-vascular cell adhesion molecule-1 (VCAM-1) pathway is critical for lesion development, because a murine model with altered ligand-binding sites of VCAM-1 has diminished lesion formation on a proatherogenic background. 7 Thus, the effects of LTB 4 on ␤ 2 -integrin expression on monocytes are unlikely to account for the demonstrated role of LTB 4 in vascular lesion development.
LTB 4 binds to its high-affinity receptor BLT1, which is present on neutrophils, eosinophils, and monocytes. 8 In the multistep paradigm of leukocyte recruitment, chemoattractants bind to their receptors on leukocytes, thereby converting rolling to firm adhesion via rapid integrin activation. 9, 10 Flow cytometric studies suggest that LTB 4 can trigger the upregulation of overall levels of surface ␤ 2 -integrins on neutrophils (polymorphonuclear cells [PMNs] ) and monocytes over the course of 10 minutes to several hours. 11, 12 Modulation of ␤ 2 -integrin expression over this time course, however, cannot account for rapid adhesive triggering. The impact of LTB 4 on rapid changes in affinity (conformation) or avidity (multivalent binding or clustering) of ␤ 2 or other integrins for their endothelial counterligands is poorly understood. In functional assays under static conditions, lipoxygenase products, including LTB 4 , increase leukocyte adhesion to endothelial monolayers. Indeed, these studies have suggested that lipoxygenase-triggered leukocyte adhesion might actually be due in large part to direct effects on human endothelial cells, although the relevant adhesive mechanisms have yet to be characterized. [13] [14] [15] Thus, the mechanisms by which LTB 4 contributes to monocyte activation and recruitment are not clearly defined. Here, we specifically addressed whether LTB 4 can trigger the rapid changes in integrin affinity and/or avidity that promote monocyte capture under dynamic conditions as seen in the bloodstream, which has not previously been investigated. In light of recent atherosclerosis studies, we also explored the effects of LTB 4 on monocyte activation of ␤ 1 -integrin-dependent pathways. Finally, in this study we studied signaling pathways triggered by LTB 4 in human monocytes and compared these with cascades activated by peptide chemoattractants such as MCP-1. Dissecting the functionally relevant steps in which LTB 4 promotes monocyte recruitment has important implications in the development of therapy for vascular diseases.
Methods

Materials
RPMI-1640 medium, Dulbecco's modified Eagle's medium, and Dulbecco's phosphate-buffered saline with or without Ca 2ϩ and Mg 2ϩ were purchased from BioWhittaker, Inc. Fetal bovine serum was obtained from Hyclone, Inc. Recombinant human MCP-1 and LTB 4 were purchased from PeproTech, Inc, and Calbiochem, respectively. The specific BLT1 receptor antagonist CP-105,696 was a kind gift from Dr H.J. Showell, Pfizer, Inc, Groton, CT. 12 The biochemical inhibitors LY294002, PD98059, SB203580, GF109203X, and BAPTA/AM were obtained from Alexis Biochemicals.
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were obtained from Clonetics Human Cell Systems and cultured in endothelial cell growth medium according to the manufacturer's instructions. For experimental use in the flow-plate apparatus, HUVECs (passages 2 to 5) were plated at confluence in 0.8-cm 2 chambers on fibronectincoated, plastic tissue-culture slides. HUVECs were infected for 48 hours with the indicated adenoviral vectors, as previously described. 16 
Recombinant Adenoviruses
The adenoviruses carrying the cDNA for the adhesion molecules E-selectin (AdE-sel), VCAM-1 (AdVCAM-1), and ICAM-1 (AdICAM-1) have been described previously. 10, 16 Large-scale production of adenovirus and determination of viral titers were performed as previously described. 16 Wild-type adenovirus contamination was excluded by the absence of polymerase chain reactiondetectable E1 sequences.
Antibodies
Antibodies for signaling studies included phospho-Akt (Cell Signaling) and total Akt (Cell Signaling), phospho-Erk-1/2 (Cell Signaling), and total Erk-1/2 (Santa Cruz). Leukocyte integrin-blocking antibodies included HP 2.1 (to ␣ 4␤1 integrins, Serotec) and TS1/18 (to ␤ 2 -integrins, a kind gift from Dr F.W. Luscinskas, Boston, Mass).
Antibodies to endothelial adhesion molecules 16 included 7A9 and H4/18 (to human E-selectin), Hu5/3 (to human ICAM-1), E1/6 (which recognizes both human and rabbit VCAM-1), and IgG 1 and IgG 2A control monoclonal antibody (PharMingen). Antibodies to monocyte epitopes included CD11a and CD11b (both fluorescein isothiocyanate labeled), CD49d (allophycocyanin labeled), CD62L (phycoerythrin labeled), and isotype-matched control antibodies (PharMingen). The HUTS-4 antibody specific to the active conformation of ␤ 1 -integrins 17 was obtained from Chemicon. The BLT1 receptor antibody (Clone 14F11) was obtained from Dr Christer Owman. 18
Western Blotting
Freshly isolated human monocytes were resuspended in RPMI-1640/1% bovine serum albumin at 10 7 cells/mL and equilibrated at 37°C for 10 minutes. Monocytes (10 6 cells per condition) were left untreated or stimulated with LTB 4 or MCP-1 at the indicated concentrations. At the indicated time points, whole-cell lysates were prepared as previously described. 19 Precleared cell lysates were boiled for 5 minutes at 100°C in sodium dodecyl sulfate (SDS) sample buffer and resolved by SDS-polyacrylamide gel electrophoresis (PAGE; 10% gels). After transfer onto nitrocellulose membranes (Schleicher and Schuell), membranes were blocked and probed with the indicated antibodies according to the manufacturer's instructions.
Monocyte Isolation
Human monocytes were purified from healthy donors by Ficoll-Hypaque density gradient centrifugation at 15°C (LSM, Organon Teknika) followed by negative-selection magnetic bead purification (Miltenyi Biotech), as previously described. 19 Monocyte preparations were Ͼ92% pure as determined by flow cytometry.
Flow Cytometry
Monocytes were resuspended in RPMI-1640/1% fetal bovine serum at 5 to 10ϫ10 7 cells/mL and equilibrated at 37°C for 10 minutes. Cells (0.5 to 1ϫ10 6 cells per condition) were either left unstimulated or treated with LTB 4 or MCP-1 (100 nmol/L for each) for 1 or 10 minutes. Reactions were stopped by addition of ice-cold 1ϫ phosphate-buffered saline without Ca 2ϩ and Mg 2ϩ /0.2% NaN 3 /2% fetal bovine serum and incubation for Ն5 minutes on ice. Monocytes were washed once with fluorescence-activated cell sorting (FACS) buffer (1ϫ phosphate-buffered saline without Ca 2ϩ and Mg 2ϩ /0.2% NaN 3 /1% fetal bovine serum) and blocked for 10 minutes in the same buffer supplemented with 10% human serum. After an incubation of 20 minutes on ice with the indicated fluorescently tagged primary antibodies, cells were washed twice in FACS buffer and fixed in 1ϫ phosphate-buffered saline without Ca 2ϩ and Mg 2ϩ /1% paraformaldehyde. For FACS analysis of whole blood, 200-L aliquots were labeled with the indicated antibodies as described earlier, followed by a 20-minute incubation with FACS lysis solution according to the manufacturer's instructions (Becton Dickinson). For analysis of ␤ 1 -integrin activation with the HUTS-4 antibody, monocytes were either left unstimulated or treated for 1 minute at 37°C in whole blood with either manganese (1 mmol/L), LTB 4 (100 nmol/L), or MCP-1 (100 nmol/L). Isotype-matched, fluorescently labeled, nonbinding antibodies were included as controls. Samples were then analyzed with a Becton-Dickinson FACS set to detect fluorescence, forward scatter, and side scatter.
Calcium Flux Studies in Monocytes
Purified human monocytes (6ϫ10 6 ) were loaded with 15 g fura-2 AM (Molecular Probes) in the dark for 30 minutes at 37°C in RPMI-1640/1% fetal bovine serum and washed twice in a buffer containing 145 mmol/L NaCl, 4 mmol/L KCl, 1 mmol/L NaHPO 4 , 0.8 mmol/L MgCl 2 , 18 mmol/L CaCl 2 , 25 mmol/L HEPES, and 22 mmol/L glucose. The data are presented as the relative ratio of fluorescence at 340 and 380 nm after stimulation of monocytes with the indicated agonist (100 nmol/L). 10, 20 
In Vitro Adhesion Assays Under Flow Conditions
Monocyte-EC interactions were analyzed in a commercially available, parallel-plate, laminar-flow chamber (Immunetics) as previously described. 19, 21 For blocking antibody studies, monocytes were incubated for 10 minutes at 4°C with the indicated antibody (10 g/mL) and then diluted with perfusion medium to 5ϫ10 5 cells/mL. For inhibitor studies, monocytes were pretreated with CP-105,696, PD98059, SB203580, GF109203X, or BAPTA/AM (all 10 mol/L for 10 minutes at 4°C) or LY 294002 (50 mol/L for 30 minutes at 16°C). When indicated, LTB 4 (1 to 100 nmol/L) was added to the flow of incoming monocytes (room temperature). Monocyte adhesion (Ͼ3 seconds) was quantified for each coverslip on at least 5 randomly chosen high-power fields 1 minute before and 1 minute after addition of the chemokine. The cells were perfused at an estimated shear stress of 2.0 dyne/cm 2 (flow rate of 0.78 mL/min). The entire period of perfusion was recorded on videotape.
Rat Mesentery Adhesion Studies
Intravital microscopy of rat mesentery vasculature was performed similar to previously described methods. 22, 23 In brief, male Sprague-Dawley rats (400 to 500 g) were anesthetized with a ketamine/ xylazine solution. After a midline abdominal incision, the mesentery was exteriorized, placed on a Plexiglas stage, kept moist with a warm saline solution, and maintained at 37°C. A fluorescence microscope (Zeiss Axioplan) was used to visualize the mesenteric microcirculation. The images were projected by a high-resolution video camera (Hamamatsu C2400, intensified CCD) onto a high-resolution video monitor (Sony). Images were recorded on a video recorder (Panasonic SVHS). The rats were allowed to stabilize for 30 minutes after surgery, and areas adjacent to 10-to 50-m-diameter postcapillary venules were chosen for observation. For each experiment, 2ϫ10 6 calcein-labeled human monocytes (untreated or pretreated with LTB 4 [10 nmol/L at 37°C for 5 minutes]) were superfused through a microcannula (KZ1106, Kent Scientific) into the mesenteric artery. We counted the number of adherent monocytes in at least 30 random 10ϫ fields within 5 minutes of introduction via the cannula, as determined offline by review of the videotape. A leukocyte was judged to be adherent when it had remained stationary for Ͼ30 seconds.
Statistical Analysis
Data are expressed as the meanϮSD. Statistical comparison of means was performed by a 2-tailed, unpaired, Student's t test. The null hypothesis was rejected at PϽ0.05.
Results
As shown in Figure 1 , 78% of purified monocytes expressed BLT1, as determined by a recently generated anti-BLT1 monoclonal antibody. 18 We examined the effects of LTB 4 on monocyte adhesion in a parallel-plate, laminar-flow model. We used adenoviral vectors that allowed us to manipulate specific EC-leukocyte interactions and studied the impact of chemokines on integrin-activated arrest. The adenoviral constructs confer expression of the specific adhesion molecule of interest without affecting other adhesion molecules or perturbing the underlying biology of the ECs. 10, 16, 19 We transfected monolayers with adenoviral constructs for either VCAM-1 or ICAM-1 to assess the relative contribution of ␤ 1and ␤ 2 -integrin-dependent firm adhesion, respectively. To enhance initial monocyte tethering, monolayers were also cotransduced with an adenoviral vector carrying the cDNA for human E-selectin (AdE-sel). 10 As shown in Figure 2A , addition of LTB 4 , at physiologically relevant concentrations markedly augmented monocyte adhesion, comparable to the augmentation seen by the chemokine MCP-1. 10 Interestingly, LTB 4 markedly enhanced both VCAM-1-and ICAM-1dependent monocyte firm arrest, suggesting rapid activation of both ␤ 1 -and ␤ 2 -integrins. To assess whether the increased adhesion conferred by LTB 4 was due to effects on the monocytes, ECs, or both, we pretreated endothelial monolayers with LTB 4 , vigorously washed them, and then performed flow assays. In contrast to prior studies performed in static assays, we saw no enhancement of monocyte arrest under physiological flow conditions (Figure 2A ). However, isolated monocytes that were pretreated with LTB 4 and then washed showed marked adhesion in the chamber (Figure 2A) , suggesting that LTB 4 was exerting its proadhesive effect directly on the leukocytes in this system. Pretreatment of monocytes with the specific BLT1 antagonist CP-105,696 5,12 inhibited LTB 4 -triggered arrest of monocytes ( Figure 2B ), demonstrating that this effect was mediated by BLT1 on monocytes.
To verify the specificity of the adhesive mechanisms that contribute to monocyte arrest in vitro, we used monoclonal antibodies to block the function of ␤ 1 -and ␤ 2 -integrins ( Figure 2C ). To block ␤ 1 -integrin-dependent interactions in these experiments, we used an antibody to ␣ 4 -integrins, which associate with the ␤ 1 -subunit. 10, 16 On monolayers transduced with VCAM-1, LTB 4 -induced firm arrest was blocked by a monoclonal antibody to ␣ 4␤1 -integrins, whereas a monoclonal antibody to ␤ 2 -integrins failed to abrogate interactions. Conversely, on monolayers transduced with ICAM-1, the monoclonal antibody to ␤ 2 -integrins significantly decreased firm adhesion, whereas the monoclonal antibody to ␣ 4␤1 -integrins had no effect.
The in vitro flow chamber allows one to dissect the contribution of specific adhesion pathways in monocyte recruitment. However, no in vitro system can mimic exactly the complex biology present in the vasculature in vivo. Thus, to validate the physiologic relevance of our findings, we also performed in vivo experiments in the rat mesentery. As shown in Figure 3 , LTB 4 -activated monocytes that were infused into the rat mesentery showed enhanced adhesion in this system as well.
Prior studies have suggested that LTB 4 might enhance recruitment of leukocytes into inflamed tissues by upregulating overall levels of leukocyte surface integrins, specifically ␤ 2 -integrin family members. 11, 12 In parallel with our functional assays, we performed flow cytometry analysis of human monocytes after stimulation with LTB 4 or MCP-1 to assess whether increases in leukocyte integrin surface expression might be playing a role in our system. We saw no changes in the levels of ␤ 1 -and ␤ 2 -integrins on isolated human monocytes at the time point (1 minute) when chemoattractants increased adhesion in our system, nor up to 10 minutes ( Figure 4A ). However, we could reproducibly demonstrate rapid changes in ␤ 1 -integrin activation after agonist exposure, as assessed by the increased binding of an available ␤ 1 -integrin activation epitope-specific antibody ( Figure 4B ). Thus, chemoattractant-triggered changes in leukocyte integrin avidity or affinity were responsible for our functional findings in the adhesion assays under physiological flow.
Finally, we investigated the signaling pathways by which LTB 4 might confer its functional effects. The phosphoinositide 3-kinase (PI 3-K) family has been implicated as a functionally critical pathway in chemokine receptor signaling. 19,24 -26 Chemokines activate PI 3-K isoforms at nanomolar concentrations. Inhibition of the PI 3-K axis, either biochemically or by genetic manipulation, decreases Figure 2 . A, LTB 4 augments ␤ 1 -and ␤ 2 -integrin-dependent monocyte adhesion under flow conditions. Human endothelial monolayers were transduced with AdE-sel and either AdVCAM-1 or AdICAM-1 to study ␤ 1 -or ␤ 2 -integrin-dependent adhesion, respectively. Forty-eight hours later, the interaction of freshly purified human monocytes with transduced monolayers was studied at 2.0 dyne/cm 2 . Firmly adherent cells in 5 randomly chosen, high-power fields were quantified 1 minute before and after addition of LTB 4 (1 to 100 nmol/L) to the chamber. In the far right of each figure, either monocytes or ECs were individually stimulated with LTB 4 and vigorously washed, and the adhesion assay was performed (nϭ4 for each condition, *PϽ0.01 vs unstimulated cells). B, LTB 4 -induced monocyte adhesion is mediated by BLT1 activation. Functional effects of LTB 4 and MCP-1 (100 nmol/L each) on ␤ 1 -and ␤ 2 -integrin-dependent adhesion of freshly purified monocytes were studied before and after pretreatment of monocytes with the specific BLT1 antagonist CP-105,696 (10 mol/L for 10 minutes at 4°C; nϭ3, * PϽ0.01 vs unstimulated, nonpretreated cells; **PϽ0.01 vs chemokine-stimulated, nonpretreated cells). C, Functional blocking monoclonal antibodies confirm the specificity of LTB 4 -induced ␤ 1 -and ␤ 2 -integrin-dependent adhesion. Freshly isolated human monocytes were pretreated with blocking monoclonal to ␣ 4␤1 -and ␤ 2 -integrins as indicated (10 g/mL for 10 minutes at 4°C). Interactions with HUVECs coexpressing E-selectin and ICAM-1 or VCAM-1 were analyzed at 2 dyne/cm 2 1 minute before and after LTB 4 (100 nmol/L) stimulation (nϭ3, * PϽ0.01 vs unstimulated, nonpretreated cells; **PϽ0.01 vs LTB 4 -stimulated, nonpretreated cells). chemokine-induced chemotaxis and adhesion of leukocyte subsets, including monocytes. As previously described, the chemokine MCP-1 activated PI 3-K, as assessed by Western blotting for the phosphorylated form of the obligate downstream target, Akt 19 ( Figure 5) . Surprisingly, we did not see any evidence of PI 3-K pathway activation triggered by LTB 4 , although calcium signaling and extracellular signal-regulated kinase activation were robustly activated by both agonists. Functional adhesion assays performed in parallel with the signaling studies showed no effect of the specific PI 3-K inhibitor LY294002 on LTB 4 -triggered monocyte arrest. In contrast, LY294002 inhibited monocyte firm adhesion triggered by MCP-1, as previously described 19 (Figure 6 ). We used inhibitors of the mitogen-activated protein kinase pathway, PD98059 (mitogen-activated protein kinase/ extracellular-signal-related kinase kinase inhibitor) and SB203580 (p38 mitogen-activated protein kinase inhibitor), as well as an inhibitor of protein kinase C (GF109203X), because these pathways have been implicated in chemoattractant signaling by other investigators. 27, 28 We also inhibited calcium signaling with BAPTA-AM, an intracellular calcium chelator. However, in our system, these agents did not inhibit firm arrest triggered by either LTB 4 or MCP-1 (data not shown).
Discussion
Although recent studies of LTB 4 have underscored its importance in multiple inflammatory models, the mechanisms by which LTB 4 enhances leukocyte recruitment remain incompletely defined. Here we show that LTB 4 is sufficient to trigger monocyte firm arrest under physiologic flow in vitro and in vivo. Studies with adenoviral vectors and blocking monoclonal antibodies showed that not only ICAM-1/␤2integrin-dependent adhesion but also VCAM-1/␤1-integrindependent adhesion is augmented by LTB 4 . Furthermore, flow cytometry studies suggest that the adhesion triggered by LTB 4 is not dependent on increases in overall levels of monocyte surface integrins but rather due to effects on leukocyte integrin affinity and/or avidity for endothelial ligands. Finally, both signaling studies and functional assays show that in contrast to the classic peptide chemokine MCP-1, LTB 4 appears to trigger effector functions in purified human monocytes in a PI 3-K-independent manner.
The data presented here are consistent with a growing body of evidence implicating LTB 4 in leukocyte recruitment. Prior studies of isolated human neutrophils and monocytes have suggested that LTB 4 can modulate overall levels of ␤ 2integrins for 10 minutes to several hours. 11, 12 Our data therefore extend prior work, because we used functional assays that mimicked the dynamic conditions in the bloodstream. This system is extremely sensitive to rapid changes in integrin activation that precede changes in levels of overall integrin surface expression. Thus, in addition to modulation of integrin surface levels, LTB 4 enhances monocyte integrin activation, a more rapidly occurring step relevant to monocyte accumulation.
Recent studies suggest that specific chemoattractants confer specific effector functions in leukocytes. 10, 29, 30 For example, certain chemokines appear more efficiently coupled to adhesion pathways, whereas others couple more effectively to pathways specific for chemotaxis. It is believed that this type of specialization of chemokines and chemokine receptors has been honed for "the opulence of host protection." 30 Rather than a system in which chemoattractant receptors subserve multiple functions, the efficiency of inflammatory cell infil- Purified human monocytes were left untreated or stimulated with LTB 4 or MCP-1 (100 nmol/L each for 30 seconds to 5 minutes at 37°C as indicated). In the upper panels, precleared whole-cell lysates were separated by SDS-PAGE, transferred onto nitrocellulose membranes, and incubated with the indicated primary antibodies as described in Methods. Below, purified human monocytes were loaded with fura-2 AM, and effects of the indicated agonist on intracellular calcium were analyzed as described in Methods. Representative data from 1 of 3 experiments are demonstrated. tration might be increased by a "division of labor" between receptors, with each subserving specific, nonredundant functions. Thus, it was not entirely anticipated that LTB 4 would trigger monocyte adhesion under physiologic flow. Understanding the specific steps in which LTB 4 enhances monocyte recruitment has important implications in defining the therapeutic windows for intervention in vascular disease.
We also demonstrate previously unappreciated effects of LTB 4 on monocyte ␤ 1 -integrin-dependent adhesion. This finding is particularly noteworthy with respect to atherosclerosis, wherein ␤ 1 -integrin-mediated monocyte recruitment appears to be most critical to lesion development. Adhesion studies performed with explanted carotid arteries from atherosclerosis-prone mice have shown a critical role for ␣ 4␤1integrins but not ␤ 2 -integrins on monocyte recruitment. 29 Furthermore, knockout studies have shown surprisingly modest effects of loss of the ICAM-1/␤ 2 -integrin pathway, in marked contrast to the VCAM-1/␤ 1 -integrin pathway, in atherosclerotic lesion development. 6, 7, 31 Thus, LTB 4triggered rapid changes of monocyte ␤ 1 -integrins, as we have demonstrated, might be the critical step in monocyte recruitment induced by the LTB 4 produced by atherosclerotic plaques. 4 The importance of ␤ 1 -integrins/VCAM-1 in recruitment to atherosclerotic lesions might also explain why PMNs are rarely observed in lesions, because PMNs express BLT1 but have low levels of the VCAM-1 counterligand ␣ 4␤1integrin. 29 Reduction of atherosclerotic lesion size by an LTB 4 receptor antagonist has been postulated to result from inhibition of LTB 4 -induced upregulation of monocyte ␤ 2integrin expression. Although we hypothesize that the LTB 4 effect on ␤ 1 -integrin activation is more relevant for monocyte capture into lesions, LTB 4 effects on ␤ 2 -integrins might participate in more chronic aspects of lesion development. Furthermore, LTB 4 -triggered rapid affinity or avidity changes of monocyte ␤ 2 -integrins might be critical for initial monocyte capture in other inflammatory pathologic conditions.
The intracellular signaling events that underlie LTB 4triggered functional phenomena are incompletely understood. One group has reported that LTB 4 -dependent lysosomal enzyme release in rat basophilic leukemia (RBL) cells transfected with BLT1 is resistant to the PI 3-K inhibitor wortmannin, 32 although others have reported contradictory findings in a similar system. 33, 34 Studies have also demonstrated that wortmannin is able to inhibit LTB 4 -triggered chemotaxis of RBL cells, 32 although at concentrations (100 nmol/L) that might invoke nonspecific inhibition of other pathways. 35 In freshly isolated human monocytes, as opposed to cultured cell lines, it is surprising that LTB 4 -triggered activation does not appear to involve the PI 3-K pathway, as demonstrated by both our signaling and functional assays. This is in contrast to peptide chemokines such as MCP-1, whose activation of PI 3-K is clearly necessary for both chemotaxis and adhesion in human monocytes. We believe that the critical difference between our work and prior studies is our use of primary human monocytes. We have previously published significant differences in PI 3-K signaling between primary human monocytes and other cell types. 19 Other investigators have also suggested important limitations of leukemic cell lines to study PI 3-K-dependent pathways, including abnormal local-ization of PI 3-K targets such as Akt and high basal levels of PI 3-K activation due to the lack of key counterregulatory pathways, such as PTEN and SHIP. 36 The spectrum of signaling pathways utilized by LTB 4 in distinct cell types and the functionally relevant pathways by which LTB 4 triggers adhesion specifically in monocytes, remain the subjects of future investigation.
Unanswered and also of obvious interest is whether the signaling pathways activated by MCP-1 and LTB 4 converge. If the signaling pathways were completely nonredundant, one might expect that coadministration of the 2 ligands would synergistically trigger adhesion. Interestingly, in preliminary studies in our laboratory, we did not observe synergy in terms of adhesion triggered by coadministration of MCP-1 and LTB 4 across a range of concentrations. In addition, pretreatment of monocytes with the specific BLT1 antagonist CP-105,696 did not impair MCP-1-triggered adhesion, thus suggesting that MCP-1-triggered responses are not downstream of BLT1 in this functional context. We anticipate that future studies with unbiased protein display technologies, specifically phosphoproteomics, will shed insight into the differential signaling mediated by lipid versus peptide chemoattractants. Finally, our data suggest that emerging therapeutic interventions aimed specifically at inhibiting the PI 3-K axis might have variable effects, depending on the local chemoattractant environment in a given pathologic process.
In contrast to prior experiments performed under static conditions, we did not observe augmented adhesion after direct activation of ECs with LTB 4 , followed by perfusion with monocytes. The presence of shear and differences between leukocyte subsets and endothelial preparations might have contributed to the findings in the present study. A more thorough characterization of BLT1 and BLTR2 receptor density and function in ECs in vitro and in vivo also merits future evaluation.
In summary, these results indicate that LTB 4 can trigger rapid changes in the avidity of both ␤ 1 -and ␤ 2 -integrins for their counterligands, thus enhancing monocyte capture under physiologic flow conditions. The intracellular signaling pathways appear to differ from the relevant pathways triggered by peptide chemokines such as MCP-1. Identification of the molecular mechanisms of monocyte recruitment by LTB 4 could provide future targets for therapeutic intervention in a host of important human inflammatory pathologic conditions.
